2 weeks Ago By ABMN Staff
Shares of Rapport Therapeutics ( NASDAQ:RAPP – Get Free Report ) rose 6.2% during mid-day trading on Friday . The stock traded as high as $21.
81 and last traded at $21.81. Approximately 57,092 shares were traded during trading, a decline of 69% from the average daily volume of 185,226 shares.
The stock had previously closed at $20.53. Wall Street Analyst Weigh In RAPP has been the topic of several recent analyst reports.
Stifel Nicolaus initiated coverage on shares of Rapport Therapeutics in a research note on Tuesday, July 2nd. They set a “buy” rating and a $35.00 target price on the stock.
Jefferies Financial Group initiated coverage on shares of Rapport Therapeutics in a research note on Tuesday, July 2nd. They set a “buy” rating and a $35.00 target price on the stock.
Finally, TD Cowen initiated coverage on shares of Rapport Therapeutics in a research note on Tuesday, July 2nd. They set a “buy” rating on the stock. Get Our Latest Research Report on Rapport Therapeutics Rapport Therapeutics Stock Performance Rapport Therapeutics ( NASDAQ:RAPP – Get Free Report ) last issued its quarterly earnings results on Thursday, August 8th.
The company reported ($1.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($1.
02). As a group, analysts predict that Rapport Therapeutics will post -3.46 EPS for the current year.
Insider Transactions at Rapport Therapeutics In other Rapport Therapeutics news, Director James Healy acquired 44,032 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The stock was bought at an average price of $24.52 per share, with a total value of $1,079,664.
64. Following the purchase, the director now owns 40,851 shares in the company, valued at $1,001,666.52.
The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link . Hedge Funds Weigh In On Rapport Therapeutics Institutional investors have recently added to or reduced their stakes in the stock. Logos Global Management LP acquired a new stake in shares of Rapport Therapeutics in the 2nd quarter worth $4,859,000.
Perceptive Advisors LLC purchased a new stake in shares of Rapport Therapeutics in the second quarter valued at about $17,403,000. The Manufacturers Life Insurance Company acquired a new stake in Rapport Therapeutics during the second quarter worth about $1,757,000. Millennium Management LLC purchased a new position in Rapport Therapeutics during the second quarter worth about $2,716,000.
Finally, Squarepoint Ops LLC acquired a new position in Rapport Therapeutics in the 2nd quarter valued at about $380,000. About Rapport Therapeutics ( Get Free Report ) Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders.
Rapport Therapeutics Inc is based in BOSTON. Further Reading Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
